Strata Critical Medical, Inc. Class A Common Stock (SRTA) Stock
NASDAQ · SRTA
Key stats
- Market cap
- $536.81M
- Price / Earnings ratio
- -21.7x
- EPS (TTM)
- -$0.30
- Volume
- Loading
- 52-week high
- $6.50
- 52-week low
- $3.95
Source: third-party data provider, as of November 13, 2026
Compare with SRTA
Recent news

MarketBeat
Strata Critical Medical Q3 Earnings Call Highlights
PositiveSRTANovember 3, 2026
MarketBeatPositive
Strata Critical Medical Q3 Earnings Call Highlights
SRTA

Zacks Investment Research
Strata Critical Medical, Inc. (SRTA) Upgraded to Buy: What Does It Mean for the Stock?
SRTAAugust 24, 2026
Zacks Investment Research
Strata Critical Medical, Inc. (SRTA) Upgraded to Buy: What Does It Mean for the Stock?
SRTA

Zacks Investment Research
Does Strata Critical Medical, Inc. (SRTA) Have the Potential to Rally 47.28% as Wall Street Analysts Expect?
SRTAAugust 24, 2026
Zacks Investment Research
Does Strata Critical Medical, Inc. (SRTA) Have the Potential to Rally 47.28% as Wall Street Analysts Expect?
SRTA

Zacks Investment Research
Can Strata Critical Medical, Inc. (SRTA) Run Higher on Rising Earnings Estimates?
SRTAAugust 6, 2026
Zacks Investment Research
Can Strata Critical Medical, Inc. (SRTA) Run Higher on Rising Earnings Estimates?
SRTA
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 72.68
- MACD 12/26/9
- 0.25
- EMA 9 of MACD
- 0.06
- MACD histogram
- 0.19
- SMA 50
- $5.01
- Price above SMA 50
- EMA 50
- $5.09
- Price above EMA 50
- SMA 200
- $5.09
- Price above SMA 200
- EMA 200
- $5.05
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
270M178M89M0
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
412M272M136M0
Revenue to Profit
2025$197.1M
Revenue$0.0
Cost of revenue$41.1M
Gross profit$0.0
Operating expenses$41.3M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

MarketBeat
Strata Critical Medical Q3 Earnings Call Highlights
PositiveSRTANovember 3, 2026
MarketBeatPositive
Strata Critical Medical Q3 Earnings Call Highlights
SRTA

Zacks Investment Research
Strata Critical Medical, Inc. (SRTA) Upgraded to Buy: What Does It Mean for the Stock?
SRTAAugust 24, 2026
Zacks Investment Research
Strata Critical Medical, Inc. (SRTA) Upgraded to Buy: What Does It Mean for the Stock?
SRTA

Zacks Investment Research
Does Strata Critical Medical, Inc. (SRTA) Have the Potential to Rally 47.28% as Wall Street Analysts Expect?
SRTAAugust 24, 2026
Zacks Investment Research
Does Strata Critical Medical, Inc. (SRTA) Have the Potential to Rally 47.28% as Wall Street Analysts Expect?
SRTA

Zacks Investment Research
Can Strata Critical Medical, Inc. (SRTA) Run Higher on Rising Earnings Estimates?
SRTAAugust 6, 2026
Zacks Investment Research
Can Strata Critical Medical, Inc. (SRTA) Run Higher on Rising Earnings Estimates?
SRTA

Zacks Investment Research
Wall Street Analysts Predict a 60% Upside in Strata Critical Medical, Inc. (SRTA): Here's What You Should Know
SRTAAugust 4, 2026
Zacks Investment Research
Wall Street Analysts Predict a 60% Upside in Strata Critical Medical, Inc. (SRTA): Here's What You Should Know
SRTA

Zacks Investment Research
Strata Critical Medical, Inc. (SRTA) Surges 8.5%: Is This an Indication of Further Gains?
SRTAJune 16, 2026
Zacks Investment Research
Strata Critical Medical, Inc. (SRTA) Surges 8.5%: Is This an Indication of Further Gains?
SRTA
News tone: automated (AI) classification of the article's content, not a price prediction.
About Strata Critical Medical, Inc. Class A Common Stock
No description available.
SectorHealthcare
IndustryMedical Care Facilities
Employees327
CEOMs. Melissa M. Tomkiel J.D.
IPO DateAug 28, 2025
HeadquartersNew York, NY
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Melissa M. Tomkiel J.D. | Co- CEO, General Counsel, Corporate Secretary & Director | 1981 |
| Mr. William A. Heyburn | Co-CEO, CFO & Director | 1989 |
| Mr. Scott M. Wunsch | Chief Executive Officer of Logistics Services | 1977 |
| Mr. Louis R. Verdetto | Chief Executive Officer of Clinical Services | 1984 |
| Mr. Mathew Schneider C.F.A. | CFO of Clinical Services & VP of Finance and Investor Relations | — |
| Mr. Hunter Senning | COO of Logistics | — |
| Mr. Amir M. Cohen | Chief Accounting & Integration Officer | 1977 |
| Mr. Keith Trepanier | Chief of Safety | — |
| Dr. Scott Silvestry | Chief Medical Officer | — |
Fundamentals
Valuation
Price-to-sales ratio3.66
Price-to-book value1.95
Profitability
Return on Equity14.00%
Return on Assets12.00%
Return on Sales16.00%
Gross margin (latest quarter)22.70%
EBITDA$56.51M
Trading
Average volume1,206,879
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 72.68
- MACD 12/26/9
- 0.25
- EMA 9 of MACD
- 0.06
- MACD histogram
- 0.19
- SMA 50
- $5.01
- Price above SMA 50
- EMA 50
- $5.09
- Price above EMA 50
- SMA 200
- $5.09
- Price above SMA 200
- EMA 200
- $5.05
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | +0.0 | +18.8 | -2.5 | -14.9 | +14.8 | |||||||
| 2026 | -1.0 | -9.3 | -6.9 | +20.1 | +24.2 | -13.9 | -4.9 | +2.0 | -4.8 | -8.1 | +40.4 |
Compare stocks
Market cap
$536.81M
-
-
-
Price / Earnings ratio
-21.70
-
-
-
Price / Sales ratio
3.66
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
1,206,879
-
-
-
Earnings per share
$-0.30
-
-
-



